Skip to main content

Table 2 Virologic outcomes

From: Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China

Parameter Total KTX-HD KTX
DAA-KTX KTX-DAA
On-treatment response [n (%)] 26 (100.0) 11 (100.0) 7 (100.0) 8 (100.0)
Time to first TnD, weeks [mean ± SD] 1.9 ± 0.6 2.2 ± 0.6 1.7 ± 0.5 1.6 ± 0.5
Virologic relapse [n (%)] 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
SVR 48 [n (%)] 26 (100.0) 11 (100.0) 7 (100.0) 8 (100.0)
Follow-up over 96 weeks after treatment cessation [n (%)] 24 (92.3) 9 (81.8) 7 (100.0) 8 (100.0)
SVR 96 [n (%)] 24 (100.0) 9 (100.0) 7 (100.0) 8 (100.0)